Emergent Biosolutions Inc (EBS) - Total Liabilities
Based on the latest financial reports, Emergent Biosolutions Inc (EBS) has total liabilities worth $796.00 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Emergent Biosolutions Inc to assess how effectively this company generates cash.
Emergent Biosolutions Inc - Total Liabilities Trend (2001–2025)
This chart illustrates how Emergent Biosolutions Inc's total liabilities have evolved over time, based on quarterly financial data. Check Emergent Biosolutions Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Emergent Biosolutions Inc Competitors by Total Liabilities
The table below lists competitors of Emergent Biosolutions Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Masoval AS
OL:MAS
|
Norway | Nkr3.34 Billion |
|
Orient Electric Limited
NSE:ORIENTELEC
|
India | Rs7.46 Billion |
|
RCE Capital Berhad
KLSE:9296
|
Malaysia | RM2.20 Billion |
|
Shanghai Menon Animal Nutrition Technology Co. Ltd.
SHE:301156
|
China | CN¥57.42 Million |
|
Globe Trade Centre S.A.
WAR:GTC
|
Poland | zł2.01 Billion |
|
Taimide Tech Inc
TW:3645
|
Taiwan | NT$1.82 Billion |
|
Zumiez Inc
NASDAQ:ZUMZ
|
USA | $334.57 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Emergent Biosolutions Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Emergent Biosolutions Inc (EBS) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Emergent Biosolutions Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Emergent Biosolutions Inc (2001–2025)
The table below shows the annual total liabilities of Emergent Biosolutions Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $796.00 Million | -12.23% |
| 2024-12-31 | $906.90 Million | -22.74% |
| 2023-12-31 | $1.17 Billion | -34.18% |
| 2022-12-31 | $1.78 Billion | +32.49% |
| 2021-12-31 | $1.35 Billion | -6.27% |
| 2020-12-31 | $1.44 Billion | +15.93% |
| 2019-12-31 | $1.24 Billion | +1.67% |
| 2018-12-31 | $1.22 Billion | +671.88% |
| 2017-12-31 | $157.86 Million | -57.78% |
| 2016-12-31 | $373.91 Million | -2.52% |
| 2015-12-31 | $383.57 Million | -2.16% |
| 2014-12-31 | $392.06 Million | +185.21% |
| 2013-12-31 | $137.47 Million | +12.58% |
| 2012-12-31 | $122.10 Million | -6.17% |
| 2011-12-31 | $130.14 Million | +2.67% |
| 2010-12-31 | $126.76 Million | +25.66% |
| 2009-12-31 | $100.87 Million | +10.32% |
| 2008-12-31 | $91.44 Million | -10.66% |
| 2007-12-31 | $102.35 Million | +2.57% |
| 2006-12-31 | $99.78 Million | +145.80% |
| 2005-12-31 | $40.59 Million | -11.95% |
| 2004-12-31 | $46.11 Million | +147.42% |
| 2002-12-31 | $18.64 Million | -67.71% |
| 2001-12-31 | $57.72 Million | -- |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more